Jeffrey D Krimmel-Morrison1, Talayeh S Ghezelayagh2, Shenyi Lian3, Yuezheng Zhang3, Jeanne Fredrickson3, Daniela Nachmanson3, Kathryn T Baker3, Marc R Radke4, Enna Hun4, Barbara M Norquist4, Mary J Emond5, Elizabeth M Swisher4, Rosa Ana Risques6. 1. Department of Medicine, University of Washington, Seattle, WA 98195, USA; Department of Pathology, University of Washington, Seattle, WA 98195, USA. 2. Department of Pathology, University of Washington, Seattle, WA 98195, USA; Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA. 3. Department of Pathology, University of Washington, Seattle, WA 98195, USA. 4. Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA. 5. Department of Statistics, University of Washington, Seattle, WA 98195, USA. 6. Department of Pathology, University of Washington, Seattle, WA 98195, USA. Electronic address: rrisques@uw.edu.
Abstract
OBJECTIVE: Pap tests hold promise as a molecular diagnostic for serous ovarian cancer, but previous studies reported limited sensitivity. Furthermore, the presence of somatic mutations in normal tissue is increasingly recognized as a challenge to the specificity of mutation-based cancer diagnostics. We applied an ultra-deep sequencing method with the goal of improving sensitivity and characterizing the landscape of low-frequency somatic TP53 mutations in Pap tests. METHODS: We used CRISPR-DS to deeply sequence (mean Duplex depth ~3000×) the TP53 gene in 30 Pap tests from 21 women without cancer and 9 women with serous ovarian carcinoma with known TP53 driver mutations. Mutations were annotated and compared to those in the TP53 cancer database. RESULTS: The tumor-derived mutation was identified in 3 of 8 Pap tests from women with ovarian cancer and intact tubes. In addition, 221 low-frequency (≲0.001) exonic TP53 mutations were identified in Pap tests from women with ovarian cancer (94 mutations) and without ovarian cancer (127 mutations). Many of these mutations resembled TP53 mutations found in cancer: they impaired protein activity, were predicted to be pathogenic, and clustered in exons 5 to 8 and hotspot codons. Cancer-like mutations were identified in all women but at higher frequency in women with ovarian cancer. CONCLUSIONS: Pap tests have low sensitivity for ovarian cancer detection and carry abundant low-frequency TP53 mutations. These mutations are more frequently pathogenic in women with ovarian cancer. Determining whether low-frequency TP53 mutations in normal gynecologic tissues are associated with an increased cancer risk warrants further study.
OBJECTIVE:Pap tests hold promise as a molecular diagnostic for serous ovarian cancer, but previous studies reported limited sensitivity. Furthermore, the presence of somatic mutations in normal tissue is increasingly recognized as a challenge to the specificity of mutation-based cancer diagnostics. We applied an ultra-deep sequencing method with the goal of improving sensitivity and characterizing the landscape of low-frequency somatic TP53 mutations in Pap tests. METHODS: We used CRISPR-DS to deeply sequence (mean Duplex depth ~3000×) the TP53 gene in 30 Pap tests from 21 women without cancer and 9 women with serous ovarian carcinoma with known TP53 driver mutations. Mutations were annotated and compared to those in the TP53cancer database. RESULTS: The tumor-derived mutation was identified in 3 of 8 Pap tests from women with ovarian cancer and intact tubes. In addition, 221 low-frequency (≲0.001) exonic TP53 mutations were identified in Pap tests from women with ovarian cancer (94 mutations) and without ovarian cancer (127 mutations). Many of these mutations resembled TP53 mutations found in cancer: they impaired protein activity, were predicted to be pathogenic, and clustered in exons 5 to 8 and hotspot codons. Cancer-like mutations were identified in all women but at higher frequency in women with ovarian cancer. CONCLUSIONS:Pap tests have low sensitivity for ovarian cancer detection and carry abundant low-frequency TP53 mutations. These mutations are more frequently pathogenic in women with ovarian cancer. Determining whether low-frequency TP53 mutations in normal gynecologic tissues are associated with an increased cancer risk warrants further study.
Authors: Tom Walsh; Silvia Casadei; Ming K Lee; Christopher C Pennil; Alex S Nord; Anne M Thornton; Wendy Roeb; Kathy J Agnew; Sunday M Stray; Anneka Wickramanayake; Barbara Norquist; Kathryn P Pennington; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher Journal: Proc Natl Acad Sci U S A Date: 2011-10-17 Impact factor: 11.205
Authors: Christopher P DeSimone; Misty E Day; Molly M Tovar; Charles S Dietrich; Mary L Eastham; Susan C Modesitt Journal: Obstet Gynecol Date: 2006-06 Impact factor: 7.661
Authors: Michael W Schmitt; Scott R Kennedy; Jesse J Salk; Edward J Fox; Joseph B Hiatt; Lawrence A Loeb Journal: Proc Natl Acad Sci U S A Date: 2012-08-01 Impact factor: 11.205
Authors: Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll Journal: N Engl J Med Date: 2014-11-26 Impact factor: 91.245
Authors: Jesse J Salk; Kaitlyn Loubet-Senear; Elisabeth Maritschnegg; Charles C Valentine; Lindsey N Williams; Jacob E Higgins; Reinhard Horvat; Adriaan Vanderstichele; Daniela Nachmanson; Kathryn T Baker; Mary J Emond; Emily Loter; Maria Tretiakova; Thierry Soussi; Lawrence A Loeb; Robert Zeillinger; Paul Speiser; Rosa Ana Risques Journal: Cell Rep Date: 2019-07-02 Impact factor: 9.423
Authors: Yuxuan Wang; Lu Li; Christopher Douville; Joshua D Cohen; Ting-Tai Yen; Isaac Kinde; Karin Sundfelt; Susanne K Kjær; Ralph H Hruban; Ie-Ming Shih; Tian-Li Wang; Robert J Kurman; Simeon Springer; Janine Ptak; Maria Popoli; Joy Schaefer; Natalie Silliman; Lisa Dobbyn; Edward J Tanner; Ana Angarita; Maria Lycke; Kirsten Jochumsen; Bahman Afsari; Ludmila Danilova; Douglas A Levine; Kris Jardon; Xing Zeng; Jocelyne Arseneau; Lili Fu; Luis A Diaz; Rachel Karchin; Cristian Tomasetti; Kenneth W Kinzler; Bert Vogelstein; Amanda N Fader; Lucy Gilbert; Nickolas Papadopoulos Journal: Sci Transl Med Date: 2018-03-21 Impact factor: 17.956
Authors: Scott R Kennedy; Rosa Ana Risques; Daniela Nachmanson; Shenyi Lian; Elizabeth K Schmidt; Michael J Hipp; Kathryn T Baker; Yuezheng Zhang; Maria Tretiakova; Kaitlyn Loubet-Senear; Brendan F Kohrn; Jesse J Salk Journal: Genome Res Date: 2018-09-19 Impact factor: 9.043
Authors: Iñigo Martincorena; Joanna C Fowler; Agnieszka Wabik; Andrew R J Lawson; Federico Abascal; Michael W J Hall; Alex Cagan; Kasumi Murai; Krishnaa Mahbubani; Michael R Stratton; Rebecca C Fitzgerald; Penny A Handford; Peter J Campbell; Kourosh Saeb-Parsy; Philip H Jones Journal: Science Date: 2018-10-18 Impact factor: 47.728
Authors: Julia Matas; Brendan Kohrn; Jeanne Fredrickson; Kelly Carter; Ming Yu; Ting Wang; Xianyong Gui; Thierry Soussi; Victor Moreno; William M Grady; Miguel A Peinado; Rosa Ana Risques Journal: Cancer Res Date: 2022-04-15 Impact factor: 13.312